Tetsuwan Scientific
Tetsuwan is at the forefront of integrating artificial intelligence with lab robotics to create autonomous platforms for life sciences research. Their innovative approach aims to bridge the communication gap between scientists and lab automation tools, facilitating a new era of scientific discovery. By automating the scientific method, Tetsuwan is positioned to revolutionize how experiments are conducted, making it easier for researchers to leverage advanced technologies in their work. The company is backed by a team of engineers with diverse expertise, including experience in synthetic biology and robotics, and is focused on developing solutions that enhance the efficiency and effectiveness of scientific research.
Tetsuwan Scientific
Tetsuwan is at the forefront of integrating artificial intelligence with lab robotics to create autonomous platforms for life sciences research. Their innovative approach aims to bridge the communication gap between scientists and lab automation tools, facilitating a new era of scientific discovery. By automating the scientific method, Tetsuwan is positioned to revolutionize how experiments are conducted, making it easier for researchers to leverage advanced technologies in their work. The company is backed by a team of engineers with diverse expertise, including experience in synthetic biology and robotics, and is focused on developing solutions that enhance the efficiency and effectiveness of scientific research.
TL;DR
What they do: Build autonomous wet‑lab robots and software (robotic AI scientists) that translate scientific intent into robotic execution
Founding year: 2023
Founders: Cristian Ponce (CEO) and Théo Schäfer (CTO)
Latest disclosed funding: Pre‑seed (~$2.7M) led by 2048 Ventures
Company Overview
Problem Domain
Life sciences research automation and lab robotics
Founded
2023
Industry
Biotechnology
Tech Stack
Funding Track Record
$2,660,000
Round reported in multiple profiles; other participating investors include Carbon Silicon Ventures, Referent Ventures, and Everywhere Ventures. TechCrunch reported a $2.7M pre‑seed.
Investor Signal
“Backed by seed‑stage VCs active in biotech and early‑stage hardware/software startups (2048 Ventures, Carbon Silicon Ventures, Referent Ventures, Everywhere Ventures)”